Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

Overview of attention for article published in New England Journal of Medicine, December 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 25 news outlets
blogs: 2 blogs
twitter: 143 X users
facebook: 1 Facebook page

reddit: 1 Redditor
bluesky: 27 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 58 Mendeley

So far, Altmetric has seen 39 news stories from 25 outlets.

Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference

Yahoo! Finance USA, 12 Jan 2026

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation…

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Business Herald Online, 12 Jan 2026

Full-year 2025 preliminary1 U.S. net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) total injection demand…

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

The Manila Times, 12 Jan 2026

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand…

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Wall Street Online Denmark, 12 Jan 2026

Full-year 2025 preliminary1 U.S. net product revenues of $689 million SYFOVRE (pegcetacoplan injection) total injection demand…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 35 additional news stories.